Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

LifeStance Health (LFST) EBIT (2020 - 2025)

LifeStance Health (LFST) has disclosed EBIT for 6 consecutive years, with -$3.5 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT fell 427.48% to -$3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a 108.21% increase, with the full-year FY2025 number at $2.6 million, up 108.21% from a year prior.
  • EBIT was -$3.5 million for Q4 2025 at LifeStance Health, down from $7.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $7.4 million in Q3 2025 to a low of -$241.1 million in Q4 2021.
  • A 5-year average of -$42.1 million and a median of -$33.2 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: plummeted 45335.58% in 2021, then soared 15665.96% in 2025.
  • LifeStance Health's EBIT stood at -$241.1 million in 2021, then soared by 80.92% to -$46.0 million in 2022, then increased by 29.86% to -$32.3 million in 2023, then skyrocketed by 103.28% to $1.1 million in 2024, then plummeted by 427.48% to -$3.5 million in 2025.
  • Per Business Quant, the three most recent readings for LFST's EBIT are -$3.5 million (Q4 2025), $7.4 million (Q3 2025), and -$2.9 million (Q2 2025).